Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK.

Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14. doi: 10.1073/pnas.1018892108. Epub 2011 Jan 31.

PMID:
21282607
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.

PMID:
20661737
[PubMed - indexed for MEDLINE]
3.

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.

Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT.

J Drug Target. 2002 Nov;10(7):539-48.

PMID:
12683721
[PubMed - indexed for MEDLINE]
4.

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.

Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25.

PMID:
19779718
[PubMed - indexed for MEDLINE]
5.

Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.

Shmeeda H, Tzemach D, Mak L, Gabizon A.

J Control Release. 2009 Jun 5;136(2):155-60. doi: 10.1016/j.jconrel.2009.02.002. Epub 2009 Feb 7.

PMID:
19331844
[PubMed - indexed for MEDLINE]
6.

[Losartan inhibited angiotensin induced human lung fibroblast transformation and collagen synthesis].

Long X, Xiong SD, Xiong WN, Xu YJ, Zhang ZX, Cao Y, Chen J, Xu XH.

Zhonghua Jie He He Hu Xi Za Zhi. 2007 Apr;30(4):273-8. Chinese.

PMID:
17651610
[PubMed - indexed for MEDLINE]
7.

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector.

McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK.

Cancer Res. 2006 Mar 1;66(5):2509-13.

PMID:
16510565
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.

Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A.

Clin Cancer Res. 1998 Feb;4(2):499-505.

PMID:
9516942
[PubMed - indexed for MEDLINE]
Free Article
9.

What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?

Grenader T, Gabizon A.

J Clin Oncol. 2010 Apr 20;28(12):e193-4; author reply e195-6. doi: 10.1200/JCO.2009.26.8052. Epub 2010 Mar 1. No abstract available.

PMID:
20194839
[PubMed - indexed for MEDLINE]
Free Article
10.

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.

Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A.

Arch Dermatol. 2000 Dec;136(12):1475-80.

PMID:
11115157
[PubMed - indexed for MEDLINE]
11.

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW.

Hum Gene Ther. 2008 Sep;19(9):873-86. doi: 10.1089/hum.2008.047.

PMID:
18710328
[PubMed - indexed for MEDLINE]
12.

Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang CL, Bradshaw AD, Brekken RA.

PLoS One. 2012;7(2):e31384. doi: 10.1371/journal.pone.0031384. Epub 2012 Feb 14.

PMID:
22348081
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pegylated liposomal doxorubicin in the treatment of breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2003 Dec;4(5):318-28. Review.

PMID:
14715106
[PubMed - indexed for MEDLINE]
14.

Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.

Markman M.

Expert Opin Pharmacother. 2006 Aug;7(11):1469-74.

PMID:
16859430
[PubMed - indexed for MEDLINE]
15.

Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P, Huang YY, Fong Y, Wong RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1519-28. doi: 10.1158/1078-0432.CCR-07-4628.

PMID:
18316577
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

17beta-estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors.

Zhou L, Shao Y, Huang Y, Yao T, Lu LM.

Eur J Pharmacol. 2007 Jul 19;567(3):186-92. Epub 2007 Apr 5.

PMID:
17511985
[PubMed - indexed for MEDLINE]
17.

PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.

Shroff K, Kokkoli E.

Langmuir. 2012 Mar 13;28(10):4729-36. doi: 10.1021/la204466g. Epub 2012 Feb 29.

PMID:
22268611
[PubMed - indexed for MEDLINE]
18.

Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.

Raki M, Hakkarainen T, Bauerschmitz GJ, Särkioja M, Desmond RA, Kanerva A, Hemminki A.

Gene Ther. 2007 Oct;14(19):1380-8. Epub 2007 Jul 5.

PMID:
17611584
[PubMed - indexed for MEDLINE]
19.

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.

Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G.

Breast Cancer Res Treat. 2009 Oct;117(3):591-8. doi: 10.1007/s10549-008-0306-9. Epub 2009 Jan 21.

PMID:
19156515
[PubMed - indexed for MEDLINE]
20.

Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.

Perez AT, Domenech GH, Frankel C, Vogel CL.

Cancer Invest. 2002;20 Suppl 2:22-9. Review.

PMID:
12442346
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk